BioSpace News Archive

PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange agreements pursuant to which it will exchange $119.3 million in aggregate principal amount of its outstanding 2.75% Convertible Senior Notes due in December 2021 (the “2021 Notes”) and in December 2024 (the “2024 Notes”) for (i) cash in an aggregate amount of $98.0 million

In a new article published in the December issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), the authors offer an in-depth analysis of the latest 3D printing technology and explore its impact on patient care.

Fluxion Biosciences announces the launch of three new targeted NGS liquid biopsy panels: Spotlight Myeloid, Spotlight EGFR, and Spotlight TP53

SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that CIGNA has established a positive coverage policy for minimally invasive SI joint fusion.

Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of December 2019, representing $0.936 per Common Share on an annualized basis.

PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Marketing Operations at Health & Wellness Partners, LLC (HWP) one of the most innovative Divisions of 2019, for its proprietary software known as the Marketing Operations Tracking System (MOTS).

The Institute for Functional Medicine (IFM) today announced that Joseph E. Pizzorno, ND, has been elected Chairman of its governing Board of Directors

The Antibacterial Resistance Leadership Group (ARLG), a unique research network for which the Duke Clinical Research Institute (DCRI) acts as a coordinating center, received a federal award worth up to $102.5 million over seven years that will continue the ARLG mission to prioritize, design, and execute clinical research to reduce the public health threat of antibacterial resistance.

The board of directors of Abbott (NYSE: ABT) today increased the company’s quarterly common dividend to 36 cents per share – a 12.5% increase.

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced an exceptional year in research, including the first published studies using samples from the Lyme Disease Biobank and advances in research of disulfiram for treating individuals suffering from chronic Lyme disease and chronic babesiosis, an approach that BAL was the first to support.